Table. 1.
Characteristics of 9 included studies (6 independent cohorts).
| Study; Study Design |
Time Period |
Total number of patients with NAFLD in cohort |
Patient characteristics | Standard Test | Index Test | ||
|---|---|---|---|---|---|---|---|
| Age, mean; Sex (% males) |
BMI, mean (SD) |
Fibrosis staging system |
Distribution of fibrosis stage (stage 0/1/2/3/4) |
Interval between MRE and liver biopsy (days) |
|||
| Rochester, Minnesota, U.S.A. – MRE Scanner – GE Medical Systems, WI, USA | |||||||
| Yin, 2007[29]; Chen, 2011[24]; Retrospective |
2005– 2007, 2007– 2010 |
15, 58 | 53 (13); 23% | 36.3 (7.9) | Brunt | Stage 0/1/2/3/4 – 35/18/4/6/10 |
33 (0–1696) |
| Chicago, Illinois, U.S.A. – MRE Scanner – Siemens Medical Solutions, Erlangen, Germany | |||||||
| Wang, 2011[28]; Rustogi, 2012[27]; Retrospective |
2008– 2009; 2008– 2011 |
8, 5 | 56 (8); 15% | 38.0 (NA) | Brunt | Stage 0/1/2/3/4 – 2/4/3/2/2 |
69 (2–372) |
| San Diego, California, U.S.A. – MRE Scanner – GE Medical Systems, WI, USA | |||||||
| Loomba, 2014[4]; Prospective |
2011– 2013 |
117 | 50 (13); 44% | 32.4 (5.0) | NASH CRN | Stage 0/1/2/3/4 – 40/43/11/16/7 |
45 (1–331) |
| Low, 2012[26]; Retrospective |
NR | 12 | 45 (16); 50% | NR | Metavir | Stage 0/1/2/3/4 – 0/4/4/2/2 |
NR |
| Cambridge, United Kingdom – MRE Scanner – GE Medical Systems, WI, USA | |||||||
| Godfrey, 2012[25]; Retrospective |
2007– 2009 |
8 | 54 (8); 88% | NR | Modified NAS fibrosis score |
Stage 0/1/2/3/4 – 1/4/1/2/0 |
1 (0) |
| Berlin, Germany – MRE Scanner – Siemens Medical Solutions, Erlangen, Germany | |||||||
| Asbach, 2008[22]; Asbach, 2010[23]; Retrospective |
2006– 2009 |
1, 8 | 50 (8); 33% | 24.0 (2.5) | Desmet | Stage 0/1/2/3/4 – 0/2/2/2/3 |
13 (2–34) |
[Abbreviations: MRE-Magnetic resonance elastography; NAFLD-Non-alcoholic fatty liver disease; NASH CRN-Non-alcoholic steatohepatitis clinical research network; NAS-NASH activity score; NR-Not reported]